Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 86Leukemia 50Gastrointestinal Stromal Tumors 41Leukemia, Myeloid, Chronic-Phase 28Precursor Cell Lymphoblastic Leukemia-Lymphoma 25Blast Crisis 17Philadelphia Chromosome 13Brain Neoplasms 12Sarcoma 10Leukemia, Myeloid, Acute 10Glioblastoma 10Lung Neoplasms 9Leukemia, Myeloid, Accelerated Phase 9Gliosarcoma 9Prostatic Neoplasms 8Neoplasms 7Neoplasm Metastasis 7Glioma 7Oligodendroglioma 6Melanoma 6Leukemia, Myelomonocytic, Chronic 6Dermatofibrosarcoma 6Astrocytoma 6Small Cell Lung Carcinoma 5Recurrence 5Primary Myelofibrosis 5Polycythemia Vera 5Ovarian Neoplasms 5Leukemia, Myeloid 5Central Nervous System Neoplasms 5

Interventions

Oxaliplatin 4Fluorouracil 4Magnetic Resonance Spectroscopy 35,10-methylenetetrahydrofolic acid 3Ocoxin 2Leucovorin 2Irinotecan 2Cyclophosphamide 2Bevacizumab 2trifluridine tipiracil drug combination 1sintilimab 1pralsetinib 1pembrolizumab 1napabucasin 1huachansu 1guadecitabine 1Ursodeoxycholic Acid 1Surveys and Questionnaires 1S-1 plus cisplatin 1Pharmaceutical Preparations 1Pemetrexed 1Paclitaxel 1Oviposition 1Levoleucovorin 1Infliximab 1Imatinib Mesylate 1Gemcitabine 1Exercise Test 1Drainage 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Gastrointestinal Diseases × Imatinib Mesylate × Clear all
NCT00867113 2018-03-14

Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)

Novartis

Phase 2 Completed
91 enrolled 11 charts
GastrointestinalSarcoma

Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡